Myasthenia Gravis Therapeutics Pipeline Analysis, 2017

  • ID: 4435223
  • Report
  • 102 pages
  • P&S Market Research
1 of 3
Myasthenia Gravis Therapeutics Pipeline in 2017

The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development. Myasthenia gravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease worsens after a period of activity and improves after a period of rest.

Strategic Collaboration for the Development of Myasthenia Gravis Therapeutics

Various companies, educational institutes and medical organizations are collaborating for the development of drugs for the treatment of this disease. For instance, Merck & Co., Inc. entered into a multi-targeted collaboration and license agreement with Ra Pharmaceuticals, Inc. to use the latter’s drug discovery technology platform for the development of orally available cyclic peptides for the treatment of myasthenia gravis.

Various Drug Candidates are Being Developed as Biologics

It has been observed that most of the drugs in the myasthenia gravis therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under development by Neurotune AG for the treatment of myasthenia gravis. The drug acts as a neuromuscular junction stimulator.

Some of the key players developing drugs for the treatment of myasthenia gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and others.

Myasthenia gravis Therapeutics Pipeline Analysis:
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1. Research Objectives
1.2. Definition
1.3. Research Scope
1.3.1. Pipeline Analysis by Phase
1.3.2. Pipeline Analysis by Molecule Type
1.3.3. Pipeline Analysis by Route of Administration
1.4. Key Stakeholders

2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.2.1. Breakdown of Primary Research Respondents
2.2.1.1. By industry participants
2.2.1.2. By company type

3. Executive Summary

4. Pipeline Outlook
4.1. IPF Disease Overview
4.1.1. Signs and Symptoms
4.1.2. PAThophysiology
4.1.3. Diagnosis
4.1.4. Treatment
4.1.5. Epidemiology
4.2. Key Drivers
4.3. Key Barriers
4.4. IdioPAThic Pulmonary Fibrosis Pipeline Analysis
4.4.1. Pipeline Analysis by Phase
4.4.2. Pipeline Analysis by Molecule Type
4.4.3. Pipeline Analysis by Route of Administration
4.4.4. Pipeline Analysis by Company
4.5. Inactive Drug Candidates
4.6. Discontinued Drug Candidates

5. IPF Therapeutics Pipeline Analysis by Phase (2017)
5.1. Phase III: Drug Profiles
5.1.1. Phase III Drugs
5.1.1.1. Pre-Clinical Studies
5.1.1.2. Clinical Trials
5.1.1.3. Clinical Trial Results
5.1.1.4. Strategic Developments
5.1.1.5. Financing
5.1.1.6. Designations
5.1.1.7. Grants
5.1.1.8. Patents
5.1.1.9. Technology
5.2. Phase II: Drug Profiles
5.2.1. Phase II Drugs
5.2.1.1. Pre-Clinical Studies
5.2.1.2. Clinical Trials
5.2.1.3. Clinical Results
5.2.1.4. Strategic Developments
5.2.1.5. Financing
5.2.1.6. Designations
5.2.1.7. Grants
5.2.1.8. Patents
5.2.1.9. Technology
5.3. Phase I: Drug Profiles
5.3.1. Phase I Drugs
5.3.1.1. Pre-Clinical Studies
5.3.1.2. Clinical Trials
5.3.1.3. Strategic Developments
5.3.1.4. Financing
5.3.1.5. Grants
5.3.1.6. Patents
5.3.1.7. Technology
5.4. Pre-Clinical: Drug Profiles
5.4.1. Pre-Clinical Studies
5.4.2. Strategic Developments
5.4.3. Financing
5.4.4. Grants
5.4.5. Patents
5.4.6. Technology
5.5. Discovery: Drug Profiles
5.5.1. Strategic Developments
5.5.2. Financing
5.5.3. Grants
5.5.4. Patents
5.5.5. Technology

6. Clinical Trials Analysis
6.1. Clinical Trials Analysis, by Region
6.2. Clinical Trials Analysis, by Trial Status

7. Competitive Landscape
7.1. Key Players Benchmarking for IPF Therapeutics Pipeline
7.2. SWOT Analysis of IPF Therapeutics Pipeline
7.2.1. Strengths
7.2.2. Weaknesses
7.2.3. Opportunities
7.2.4. Threats

8. Company Profiles
8.1. Companies having Pipeline of IPF Therapeutics
8.1.1. Business Overview
8.1.2. Product and Service Offerings

9. Appendix
9.1. Abbreviations
9.2. Related Reports

Note: Certain sections of the above table of contents would vary according to the availability of information.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll